Clinical trials: Stage III
Plasmacytoma
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
The purpose of the trial is to establish whether adjuvant therapy with lenalidomide + dexamethasone after radiotherapy can improve progression free survival in patients with high risk solitary bone plasmacytoma compared with RT…
- Trial name
- IDRIS (NCT02544308)
- Testing
- Lenalidomide, Dexamethasone, No further treatment
- Where
- 13 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- University College, London
Breast Cancer
Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women
Breast cancer is the second most frequent cancer worldwide. Principal therapy consists in radiotherapy, but this technic has sides effects as radiodermatitis, concerning about 90 percent of women treated.
- Trial name
- HOMEORAD (NCT03753776)
- Testing
- Radium bromatum pills, Radium bromatum/Apis mellifica/Belladonna pills
- Where
- France
- Volunteers
- 232 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002717
- Testing
- cisplatin, paclitaxel
- Where
- 52 sites in United States
- Volunteers
- 324 people
- Sponsor
- Gynecologic Oncology Group
Stage IB Skin Melanoma, Stage IIA Skin Melanoma
Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
This pilot clinical trial studies intravital microscopy in identifying tumor vessels in patients with stage IB-IIIC melanoma undergoing sentinel lymph node biopsy.
- Conditions
- Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma
- Trial name
- NCT02857374
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Hepatocellular
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
This was a multicenter, randomized, double-blind, phase III trial. This clinical study evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have progressed on Systemic Therapy (Chemotherapy…
- Trial name
- NCT02329860
- Testing
- Apatinib
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00309920
- Testing
- darbepoetin alfa, cyclophosphamide, docetaxel
- Where
- 47 sites in Germany
- Volunteers
- 1,234 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Grade/Stage I Hemorrhoids, Prolapsed Grade II Internal Haemorrhoid
A Multicenter Prospective Clinical Study of Endoscopic Foam Sclerotherapy for Internal Hemorrhoids
"Internal hemorrhoid" affects the quality of life due to hemorrhage and prolapse as a common and frequently-occurring disease. Endoscopic sclerosing agent injection has replaced traditional surgery and become the most commonly…
- Conditions
- Grade/Stage I Hemorrhoids, Prolapsed Grade II Internal Haemorrhoid, Prolapsed Grade III Internal Haemorrhoid
- Trial name
- NCT04398823
- Testing
- Sclerosing foam of Lauromacrogol, Sclersing liqiud of Lauromacrogol
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Carcinoma, Hepatocellular
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no…
- Trial name
- IMbrave150 (NCT03434379)
- Testing
- Atezolizumab, Bevacizumab, Sorafenib
- Where
- 119 sites in United States, Australia and 15 more
- Volunteers
- 558 people
- Sponsor
- Hoffmann-La Roche
Typhoid
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
This is a multicenter, randomized, observer-blinded, controlled, immune equivalence study of a multi-dose (MD) formulation with 2PE preservative of SK bioscience Vi-DT compared to single dose (SD) formulation without preservative…
- Trial name
- NCT04204096
- Testing
- Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine
- Where
- 4 sites in Philippines
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
NSCLC (Non-small Cell Lung Cancer)
D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
This study is a single-arm prospective single-center phase II study. Subjects are untreated resectable stage II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC.
- Trial name
- NCT07016126
- Testing
- D-BACE in combination with chemotherapy and karelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Guangdong Provincial People's Hospital
Mixed Dyslipidemias
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia
Efficacy and safety of combination therapy of rosuvastatin and fenofibrate versus rosuvastatin monotherapy in mixed dyslipidemia patients: A randomized, multi-center, double-blind, phase 3 study
- Trial name
- NCT02262143
- Testing
- Rosuvastatin, Fenofibrate
- Where
- South Korea
- Volunteers
- 362 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Chondral or Osteochondral Lesion of Talus
Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus
The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar…
- Trial name
- NCT04310215
- Testing
- CARTISTEM®, Microfracture
- Where
- 6 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- Hyundai Bioland Co., Ltd.
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT00698815
- Testing
- Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate
- Where
- 129 sites in United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
This is a a phase III, randomized, open-label clinical trial comparing endocrine therapy combined with high-dose palbociclib and hydroxychloroquine to endocrine therapy combined with standard-dose palbociclib for hormone…
- Trial name
- NCT07061717
- Testing
- Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid, Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
This phase Ib/II trial studies the best dose of temozolomide and how well it works with niraparib and atezolizumab in treating patients with solid tumors that have spread to other places in the body (advanced) and extensive-stage…
- Conditions
- Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03830918
- Testing
- Atezolizumab, Niraparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Jonsson Comprehensive Cancer Center
HER2-positive Breast Cancer
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety and Immunogenicity of Vinorelbine Bitartrate Injection in Combination With HS022 and Trastuzumab®.There were 2 parts.
- Trial name
- NCT06107790
- Testing
- HS022, Trastuzumab, Vinorelbine Bitartrate
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus…
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- OPTIMA (NCT02258659)
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Chicago
Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has…
- Conditions
- Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT02254278
- Testing
- Cisplatin, IMRT 6 weeks, IMRT 5 weeks
- Where
- 222 sites in United States, Canada and 2 more
- Volunteers
- 316 people
- Sponsor
- NRG Oncology
NSCLC Non-small Cell Lung Cancer
Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
The objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy (with cisplatin/docetaxel) in primary…
- Trial name
- NCT02572843
- Testing
- MEDI4736 (anti-PD-L1)
- Where
- 19 sites in Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to…
- Conditions
- Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05256225
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 414 sites in United States, Puerto Rico and 1 more
- Volunteers
- 360 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.